The FDA granted Rigel Pharmaceuticals (RIGL) orphan status for its treatment of myelodysplastic syndromes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel Pharmaceuticals price target raised to $25 from $15 at Cantor Fitzgerald
- Rigel Pharmaceuticals price target lowered to $20 from $27 at B. Riley
- Rigel Pharmaceuticals announces initial data from Phase 1b study of R289
- Rigel Pharmaceuticals price target raised to $27 from $17 at B. Riley
- Rigel Pharmaceuticals announces R289 granted Fast Track designation by FDA